Navigation Links
Sanofi Pasteur to Acquire VaxDesign, a U.S. Biotechnology Company
Date:9/27/2010

lorida, that develops, manufactures, and markets in vitro models of the human immune system. Its Modular IMmune In vitro Construct (MIMIC(R)) technology melds immunology with engineering to find elegant solutions to complex biological problems. The MIMIC(R) system was initially developed for the Rapid Vaccine Assessment Program of the U.S. Defense Advanced Research Projects Agency (DARPA) and has since been funded by several other U.S. federal agencies, such as the Defense Threat Reduction Agency, Biomedical Advanced Research and Development Authority, Army Chemical Biological Medical Systems (CBMS), and National Institute of Standards and Technology (NIST).

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). For more information, please visit: www.sanofi-aventis.com

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than 1.6 billion doses of vaccine in 2009, making it possible to immunize more than 500 million people across the globe. A world leader in the vaccine industry, Sanofi Pasteur offers the broadest range of vaccines protecting against 20 infectious diseases. The company's heritage, to create vaccines that protect life, dates back more than a century. Sanofi Pasteur is the largest company entirely dedicated to vaccines. Every day, the company invests more than EUR 1 million in research and development. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are
'/>"/>

SOURCE Sanofi Pasteur
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
2. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
3. Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
4. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
5. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
6. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
7. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
8. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
9. Sanofi Pasteur Responds to Nations Need for Hib Vaccine With Increased Supply
10. Sanofi-aventis Announces Second Quarter 2009 Results
11. Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... and the field of polymer science and engineering ... unique properties and processing advantages, which are unattainable ... advances in polymer science and engineering will be ... energy, sustainability, clean water, food preservation, healthcare, informatics, ...
... LAFAYETTE, Ind. ╨ Engineers have discovered details about the behavior ... in manufacturing, diagnostics and other research., ... and surface textures in metals, ceramics and other materials for ... lasers pulse at durations of 100 femtoseconds, or quadrillionths of ...
... Corporation (NYSE: CO ) ("CCBC" or the "Company"), ... China, today announced the results of its 2011 Annual General ... Kong. At the Annual General Meeting, shareholders ... Lu to serve on the Board of Directors until the ...
Cached Biology Technology:Research and education success earns more NSF funding 2Research and education success earns more NSF funding 3Research could improve laser-manufacturing technique 2China Cord Blood Corporation Announces Results of 2011 Annual General Meeting 2
(Date:10/16/2014)... NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market announces ... the Smart Wallet, at the 13 th annual ... global conference on the intersection of technology and the ... , founder and publisher of the Strategic News Service™, ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
(Date:10/14/2014)... cancer tumors scavenge and hoard copper that is an ... be a fatal weakness. , Researchers at Duke ... cells by delivering a trove of copper along with ... with the mineral, leaving non-cancer cells healthy. , The ... for other uses, could soon be tested in clinical ...
Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
... the National Institutes of Health (NIH) have determined the ... Borrelia burgdorferi , the bacteria that cause Lyme disease. ... how genetic variations among strains may result in different ... most common tickborne disease in North America. The wealth ...
... 2010 - Alcohol is one of the most commonly ... likely to develop alcoholism as women. Until now, the ... remained unclear. A new study published in Biological ... factor. Researchers from Columbia and Yale studied male and ...
... understand the effects of climate change on the microbial ... and the tundra in Alaska, a University of Oklahoma ... of Energy grant. According to Jizhong Zhou, OU ... Institute for Environmental Genomics, the results of these studies ...
Cached Biology News:Why are men more susceptible to alcoholism? 2
...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Biology Products: